nodes	percent_of_prediction	percent_of_DWPC	metapath
Zolmitriptan—Melatonin—MT3—urinary bladder cancer	0.0185	0.688	CrCbGaD
Zolmitriptan—Melatonin—MPO—urinary bladder cancer	0.00479	0.178	CrCbGaD
Zolmitriptan—Melatonin—ESR1—urinary bladder cancer	0.00359	0.134	CrCbGaD
Zolmitriptan—Photosensitivity reaction—Doxorubicin—urinary bladder cancer	0.000584	0.000601	CcSEcCtD
Zolmitriptan—Weight increased—Doxorubicin—urinary bladder cancer	0.000583	0.000599	CcSEcCtD
Zolmitriptan—Epistaxis—Epirubicin—urinary bladder cancer	0.000582	0.000598	CcSEcCtD
Zolmitriptan—Pruritus—Gemcitabine—urinary bladder cancer	0.000582	0.000598	CcSEcCtD
Zolmitriptan—Nausea—Thiotepa—urinary bladder cancer	0.00058	0.000597	CcSEcCtD
Zolmitriptan—Urethral disorder—Methotrexate—urinary bladder cancer	0.00058	0.000597	CcSEcCtD
Zolmitriptan—Sinusitis—Epirubicin—urinary bladder cancer	0.000579	0.000595	CcSEcCtD
Zolmitriptan—Feeling abnormal—Etoposide—urinary bladder cancer	0.000578	0.000595	CcSEcCtD
Zolmitriptan—Hyperglycaemia—Doxorubicin—urinary bladder cancer	0.000577	0.000594	CcSEcCtD
Zolmitriptan—Pneumonia—Doxorubicin—urinary bladder cancer	0.000574	0.00059	CcSEcCtD
Zolmitriptan—Gastrointestinal pain—Etoposide—urinary bladder cancer	0.000574	0.00059	CcSEcCtD
Zolmitriptan—Pruritus—Fluorouracil—urinary bladder cancer	0.000572	0.000588	CcSEcCtD
Zolmitriptan—Hypersensitivity—Cisplatin—urinary bladder cancer	0.000564	0.00058	CcSEcCtD
Zolmitriptan—Bradycardia—Epirubicin—urinary bladder cancer	0.000564	0.00058	CcSEcCtD
Zolmitriptan—Diarrhoea—Gemcitabine—urinary bladder cancer	0.000562	0.000578	CcSEcCtD
Zolmitriptan—Neuropathy peripheral—Doxorubicin—urinary bladder cancer	0.000559	0.000575	CcSEcCtD
Zolmitriptan—Urticaria—Etoposide—urinary bladder cancer	0.000558	0.000573	CcSEcCtD
Zolmitriptan—Stomatitis—Doxorubicin—urinary bladder cancer	0.000556	0.000572	CcSEcCtD
Zolmitriptan—Jaundice—Doxorubicin—urinary bladder cancer	0.000556	0.000572	CcSEcCtD
Zolmitriptan—Rhinitis—Epirubicin—urinary bladder cancer	0.000555	0.000571	CcSEcCtD
Zolmitriptan—Abdominal pain—Etoposide—urinary bladder cancer	0.000555	0.000571	CcSEcCtD
Zolmitriptan—Body temperature increased—Etoposide—urinary bladder cancer	0.000555	0.000571	CcSEcCtD
Zolmitriptan—Conjunctivitis—Doxorubicin—urinary bladder cancer	0.000555	0.000571	CcSEcCtD
Zolmitriptan—Urinary tract infection—Doxorubicin—urinary bladder cancer	0.000555	0.000571	CcSEcCtD
Zolmitriptan—Diarrhoea—Fluorouracil—urinary bladder cancer	0.000553	0.000569	CcSEcCtD
Zolmitriptan—Tinnitus—Methotrexate—urinary bladder cancer	0.000552	0.000567	CcSEcCtD
Zolmitriptan—Hypoaesthesia—Epirubicin—urinary bladder cancer	0.000551	0.000567	CcSEcCtD
Zolmitriptan—Asthenia—Cisplatin—urinary bladder cancer	0.00055	0.000565	CcSEcCtD
Zolmitriptan—Pharyngitis—Epirubicin—urinary bladder cancer	0.00055	0.000565	CcSEcCtD
Zolmitriptan—Cardiac disorder—Methotrexate—urinary bladder cancer	0.000549	0.000565	CcSEcCtD
Zolmitriptan—Sweating—Doxorubicin—urinary bladder cancer	0.000547	0.000563	CcSEcCtD
Zolmitriptan—Urinary tract disorder—Epirubicin—urinary bladder cancer	0.000547	0.000562	CcSEcCtD
Zolmitriptan—Oedema peripheral—Epirubicin—urinary bladder cancer	0.000546	0.000561	CcSEcCtD
Zolmitriptan—Haematuria—Doxorubicin—urinary bladder cancer	0.000544	0.00056	CcSEcCtD
Zolmitriptan—Connective tissue disorder—Epirubicin—urinary bladder cancer	0.000544	0.00056	CcSEcCtD
Zolmitriptan—Urethral disorder—Epirubicin—urinary bladder cancer	0.000543	0.000558	CcSEcCtD
Zolmitriptan—Epistaxis—Doxorubicin—urinary bladder cancer	0.000538	0.000554	CcSEcCtD
Zolmitriptan—Angiopathy—Methotrexate—urinary bladder cancer	0.000537	0.000552	CcSEcCtD
Zolmitriptan—Sinusitis—Doxorubicin—urinary bladder cancer	0.000535	0.000551	CcSEcCtD
Zolmitriptan—Immune system disorder—Methotrexate—urinary bladder cancer	0.000534	0.00055	CcSEcCtD
Zolmitriptan—Dizziness—Fluorouracil—urinary bladder cancer	0.000534	0.00055	CcSEcCtD
Zolmitriptan—Chills—Methotrexate—urinary bladder cancer	0.000531	0.000546	CcSEcCtD
Zolmitriptan—Diarrhoea—Cisplatin—urinary bladder cancer	0.000524	0.000539	CcSEcCtD
Zolmitriptan—Vomiting—Gemcitabine—urinary bladder cancer	0.000523	0.000537	CcSEcCtD
Zolmitriptan—Bradycardia—Doxorubicin—urinary bladder cancer	0.000522	0.000536	CcSEcCtD
Zolmitriptan—Rash—Gemcitabine—urinary bladder cancer	0.000518	0.000533	CcSEcCtD
Zolmitriptan—Dermatitis—Gemcitabine—urinary bladder cancer	0.000518	0.000532	CcSEcCtD
Zolmitriptan—Hypersensitivity—Etoposide—urinary bladder cancer	0.000517	0.000532	CcSEcCtD
Zolmitriptan—Tinnitus—Epirubicin—urinary bladder cancer	0.000516	0.000531	CcSEcCtD
Zolmitriptan—Erythema—Methotrexate—urinary bladder cancer	0.000515	0.00053	CcSEcCtD
Zolmitriptan—Headache—Gemcitabine—urinary bladder cancer	0.000515	0.00053	CcSEcCtD
Zolmitriptan—Cardiac disorder—Epirubicin—urinary bladder cancer	0.000514	0.000529	CcSEcCtD
Zolmitriptan—Vomiting—Fluorouracil—urinary bladder cancer	0.000514	0.000528	CcSEcCtD
Zolmitriptan—Rhinitis—Doxorubicin—urinary bladder cancer	0.000514	0.000528	CcSEcCtD
Zolmitriptan—Hypoaesthesia—Doxorubicin—urinary bladder cancer	0.00051	0.000524	CcSEcCtD
Zolmitriptan—Rash—Fluorouracil—urinary bladder cancer	0.00051	0.000524	CcSEcCtD
Zolmitriptan—Dermatitis—Fluorouracil—urinary bladder cancer	0.000509	0.000524	CcSEcCtD
Zolmitriptan—Pharyngitis—Doxorubicin—urinary bladder cancer	0.000509	0.000523	CcSEcCtD
Zolmitriptan—Headache—Fluorouracil—urinary bladder cancer	0.000506	0.000521	CcSEcCtD
Zolmitriptan—Urinary tract disorder—Doxorubicin—urinary bladder cancer	0.000506	0.00052	CcSEcCtD
Zolmitriptan—Oedema peripheral—Doxorubicin—urinary bladder cancer	0.000505	0.000519	CcSEcCtD
Zolmitriptan—Dysgeusia—Methotrexate—urinary bladder cancer	0.000504	0.000519	CcSEcCtD
Zolmitriptan—Asthenia—Etoposide—urinary bladder cancer	0.000504	0.000518	CcSEcCtD
Zolmitriptan—Connective tissue disorder—Doxorubicin—urinary bladder cancer	0.000504	0.000518	CcSEcCtD
Zolmitriptan—Angiopathy—Epirubicin—urinary bladder cancer	0.000502	0.000517	CcSEcCtD
Zolmitriptan—Urethral disorder—Doxorubicin—urinary bladder cancer	0.000502	0.000517	CcSEcCtD
Zolmitriptan—Immune system disorder—Epirubicin—urinary bladder cancer	0.0005	0.000514	CcSEcCtD
Zolmitriptan—Back pain—Methotrexate—urinary bladder cancer	0.000498	0.000512	CcSEcCtD
Zolmitriptan—Chills—Epirubicin—urinary bladder cancer	0.000497	0.000511	CcSEcCtD
Zolmitriptan—Pruritus—Etoposide—urinary bladder cancer	0.000497	0.000511	CcSEcCtD
Zolmitriptan—Arrhythmia—Epirubicin—urinary bladder cancer	0.000495	0.000509	CcSEcCtD
Zolmitriptan—Nausea—Gemcitabine—urinary bladder cancer	0.000488	0.000502	CcSEcCtD
Zolmitriptan—Vomiting—Cisplatin—urinary bladder cancer	0.000487	0.000501	CcSEcCtD
Zolmitriptan—Rash—Cisplatin—urinary bladder cancer	0.000483	0.000497	CcSEcCtD
Zolmitriptan—Dermatitis—Cisplatin—urinary bladder cancer	0.000483	0.000496	CcSEcCtD
Zolmitriptan—Erythema—Epirubicin—urinary bladder cancer	0.000482	0.000496	CcSEcCtD
Zolmitriptan—Diarrhoea—Etoposide—urinary bladder cancer	0.00048	0.000494	CcSEcCtD
Zolmitriptan—Nausea—Fluorouracil—urinary bladder cancer	0.00048	0.000494	CcSEcCtD
Zolmitriptan—Ill-defined disorder—Methotrexate—urinary bladder cancer	0.000478	0.000491	CcSEcCtD
Zolmitriptan—Tinnitus—Doxorubicin—urinary bladder cancer	0.000478	0.000491	CcSEcCtD
Zolmitriptan—Cardiac disorder—Doxorubicin—urinary bladder cancer	0.000476	0.000489	CcSEcCtD
Zolmitriptan—Tension—Epirubicin—urinary bladder cancer	0.000473	0.000486	CcSEcCtD
Zolmitriptan—Dysgeusia—Epirubicin—urinary bladder cancer	0.000472	0.000485	CcSEcCtD
Zolmitriptan—Nervousness—Epirubicin—urinary bladder cancer	0.000468	0.000481	CcSEcCtD
Zolmitriptan—Back pain—Epirubicin—urinary bladder cancer	0.000466	0.00048	CcSEcCtD
Zolmitriptan—Angiopathy—Doxorubicin—urinary bladder cancer	0.000465	0.000478	CcSEcCtD
Zolmitriptan—Malaise—Methotrexate—urinary bladder cancer	0.000465	0.000478	CcSEcCtD
Zolmitriptan—Dizziness—Etoposide—urinary bladder cancer	0.000464	0.000477	CcSEcCtD
Zolmitriptan—Muscle spasms—Epirubicin—urinary bladder cancer	0.000463	0.000477	CcSEcCtD
Zolmitriptan—Immune system disorder—Doxorubicin—urinary bladder cancer	0.000463	0.000476	CcSEcCtD
Zolmitriptan—Vertigo—Methotrexate—urinary bladder cancer	0.000463	0.000476	CcSEcCtD
Zolmitriptan—Leukopenia—Methotrexate—urinary bladder cancer	0.000461	0.000474	CcSEcCtD
Zolmitriptan—Chills—Doxorubicin—urinary bladder cancer	0.00046	0.000473	CcSEcCtD
Zolmitriptan—Arrhythmia—Doxorubicin—urinary bladder cancer	0.000458	0.000471	CcSEcCtD
Zolmitriptan—Nausea—Cisplatin—urinary bladder cancer	0.000455	0.000468	CcSEcCtD
Zolmitriptan—Cough—Methotrexate—urinary bladder cancer	0.000449	0.000462	CcSEcCtD
Zolmitriptan—Ill-defined disorder—Epirubicin—urinary bladder cancer	0.000447	0.00046	CcSEcCtD
Zolmitriptan—Convulsion—Methotrexate—urinary bladder cancer	0.000446	0.000459	CcSEcCtD
Zolmitriptan—Vomiting—Etoposide—urinary bladder cancer	0.000446	0.000459	CcSEcCtD
Zolmitriptan—Erythema—Doxorubicin—urinary bladder cancer	0.000446	0.000459	CcSEcCtD
Zolmitriptan—Agitation—Epirubicin—urinary bladder cancer	0.000443	0.000456	CcSEcCtD
Zolmitriptan—Rash—Etoposide—urinary bladder cancer	0.000443	0.000455	CcSEcCtD
Zolmitriptan—Dermatitis—Etoposide—urinary bladder cancer	0.000442	0.000455	CcSEcCtD
Zolmitriptan—Headache—Etoposide—urinary bladder cancer	0.00044	0.000452	CcSEcCtD
Zolmitriptan—Chest pain—Methotrexate—urinary bladder cancer	0.000439	0.000451	CcSEcCtD
Zolmitriptan—Arthralgia—Methotrexate—urinary bladder cancer	0.000439	0.000451	CcSEcCtD
Zolmitriptan—Myalgia—Methotrexate—urinary bladder cancer	0.000439	0.000451	CcSEcCtD
Zolmitriptan—Tension—Doxorubicin—urinary bladder cancer	0.000438	0.00045	CcSEcCtD
Zolmitriptan—Dysgeusia—Doxorubicin—urinary bladder cancer	0.000437	0.000449	CcSEcCtD
Zolmitriptan—Malaise—Epirubicin—urinary bladder cancer	0.000435	0.000447	CcSEcCtD
Zolmitriptan—Discomfort—Methotrexate—urinary bladder cancer	0.000433	0.000446	CcSEcCtD
Zolmitriptan—Nervousness—Doxorubicin—urinary bladder cancer	0.000433	0.000446	CcSEcCtD
Zolmitriptan—Vertigo—Epirubicin—urinary bladder cancer	0.000433	0.000445	CcSEcCtD
Zolmitriptan—Syncope—Epirubicin—urinary bladder cancer	0.000432	0.000445	CcSEcCtD
Zolmitriptan—Leukopenia—Epirubicin—urinary bladder cancer	0.000431	0.000444	CcSEcCtD
Zolmitriptan—Back pain—Doxorubicin—urinary bladder cancer	0.000431	0.000444	CcSEcCtD
Zolmitriptan—Muscle spasms—Doxorubicin—urinary bladder cancer	0.000429	0.000441	CcSEcCtD
Zolmitriptan—Palpitations—Epirubicin—urinary bladder cancer	0.000426	0.000438	CcSEcCtD
Zolmitriptan—Confusional state—Methotrexate—urinary bladder cancer	0.000424	0.000436	CcSEcCtD
Zolmitriptan—Loss of consciousness—Epirubicin—urinary bladder cancer	0.000424	0.000436	CcSEcCtD
Zolmitriptan—Cough—Epirubicin—urinary bladder cancer	0.000421	0.000433	CcSEcCtD
Zolmitriptan—Anaphylactic shock—Methotrexate—urinary bladder cancer	0.00042	0.000432	CcSEcCtD
Zolmitriptan—Convulsion—Epirubicin—urinary bladder cancer	0.000418	0.00043	CcSEcCtD
Zolmitriptan—Infection—Methotrexate—urinary bladder cancer	0.000418	0.00043	CcSEcCtD
Zolmitriptan—Nausea—Etoposide—urinary bladder cancer	0.000417	0.000429	CcSEcCtD
Zolmitriptan—Hypertension—Epirubicin—urinary bladder cancer	0.000416	0.000428	CcSEcCtD
Zolmitriptan—Ill-defined disorder—Doxorubicin—urinary bladder cancer	0.000414	0.000426	CcSEcCtD
Zolmitriptan—Nervous system disorder—Methotrexate—urinary bladder cancer	0.000412	0.000424	CcSEcCtD
Zolmitriptan—Thrombocytopenia—Methotrexate—urinary bladder cancer	0.000412	0.000423	CcSEcCtD
Zolmitriptan—Arthralgia—Epirubicin—urinary bladder cancer	0.00041	0.000422	CcSEcCtD
Zolmitriptan—Myalgia—Epirubicin—urinary bladder cancer	0.00041	0.000422	CcSEcCtD
Zolmitriptan—Chest pain—Epirubicin—urinary bladder cancer	0.00041	0.000422	CcSEcCtD
Zolmitriptan—Agitation—Doxorubicin—urinary bladder cancer	0.00041	0.000422	CcSEcCtD
Zolmitriptan—Anxiety—Epirubicin—urinary bladder cancer	0.000409	0.000421	CcSEcCtD
Zolmitriptan—Skin disorder—Methotrexate—urinary bladder cancer	0.000408	0.00042	CcSEcCtD
Zolmitriptan—Hyperhidrosis—Methotrexate—urinary bladder cancer	0.000406	0.000418	CcSEcCtD
Zolmitriptan—Discomfort—Epirubicin—urinary bladder cancer	0.000405	0.000417	CcSEcCtD
Zolmitriptan—Malaise—Doxorubicin—urinary bladder cancer	0.000402	0.000414	CcSEcCtD
Zolmitriptan—Dry mouth—Epirubicin—urinary bladder cancer	0.000401	0.000413	CcSEcCtD
Zolmitriptan—Vertigo—Doxorubicin—urinary bladder cancer	0.000401	0.000412	CcSEcCtD
Zolmitriptan—Anorexia—Methotrexate—urinary bladder cancer	0.000401	0.000412	CcSEcCtD
Zolmitriptan—Syncope—Doxorubicin—urinary bladder cancer	0.0004	0.000411	CcSEcCtD
Zolmitriptan—Leukopenia—Doxorubicin—urinary bladder cancer	0.000399	0.000411	CcSEcCtD
Zolmitriptan—Confusional state—Epirubicin—urinary bladder cancer	0.000397	0.000408	CcSEcCtD
Zolmitriptan—Palpitations—Doxorubicin—urinary bladder cancer	0.000394	0.000405	CcSEcCtD
Zolmitriptan—Oedema—Epirubicin—urinary bladder cancer	0.000393	0.000405	CcSEcCtD
Zolmitriptan—Anaphylactic shock—Epirubicin—urinary bladder cancer	0.000393	0.000405	CcSEcCtD
Zolmitriptan—Loss of consciousness—Doxorubicin—urinary bladder cancer	0.000392	0.000403	CcSEcCtD
Zolmitriptan—Infection—Epirubicin—urinary bladder cancer	0.000391	0.000402	CcSEcCtD
Zolmitriptan—Cough—Doxorubicin—urinary bladder cancer	0.000389	0.0004	CcSEcCtD
Zolmitriptan—Shock—Epirubicin—urinary bladder cancer	0.000387	0.000398	CcSEcCtD
Zolmitriptan—Convulsion—Doxorubicin—urinary bladder cancer	0.000386	0.000397	CcSEcCtD
Zolmitriptan—Nervous system disorder—Epirubicin—urinary bladder cancer	0.000386	0.000397	CcSEcCtD
Zolmitriptan—Thrombocytopenia—Epirubicin—urinary bladder cancer	0.000385	0.000396	CcSEcCtD
Zolmitriptan—Hypertension—Doxorubicin—urinary bladder cancer	0.000385	0.000396	CcSEcCtD
Zolmitriptan—Tachycardia—Epirubicin—urinary bladder cancer	0.000384	0.000395	CcSEcCtD
Zolmitriptan—Musculoskeletal discomfort—Methotrexate—urinary bladder cancer	0.000383	0.000394	CcSEcCtD
Zolmitriptan—Skin disorder—Epirubicin—urinary bladder cancer	0.000382	0.000393	CcSEcCtD
Zolmitriptan—Hyperhidrosis—Epirubicin—urinary bladder cancer	0.00038	0.000391	CcSEcCtD
Zolmitriptan—Insomnia—Methotrexate—urinary bladder cancer	0.00038	0.000391	CcSEcCtD
Zolmitriptan—Chest pain—Doxorubicin—urinary bladder cancer	0.00038	0.000391	CcSEcCtD
Zolmitriptan—Arthralgia—Doxorubicin—urinary bladder cancer	0.00038	0.000391	CcSEcCtD
Zolmitriptan—Myalgia—Doxorubicin—urinary bladder cancer	0.00038	0.000391	CcSEcCtD
Zolmitriptan—Anxiety—Doxorubicin—urinary bladder cancer	0.000378	0.000389	CcSEcCtD
Zolmitriptan—Paraesthesia—Methotrexate—urinary bladder cancer	0.000377	0.000388	CcSEcCtD
Zolmitriptan—Discomfort—Doxorubicin—urinary bladder cancer	0.000375	0.000386	CcSEcCtD
Zolmitriptan—Anorexia—Epirubicin—urinary bladder cancer	0.000375	0.000386	CcSEcCtD
Zolmitriptan—Dyspnoea—Methotrexate—urinary bladder cancer	0.000375	0.000385	CcSEcCtD
Zolmitriptan—Somnolence—Methotrexate—urinary bladder cancer	0.000374	0.000384	CcSEcCtD
Zolmitriptan—Dry mouth—Doxorubicin—urinary bladder cancer	0.000371	0.000382	CcSEcCtD
Zolmitriptan—Dyspepsia—Methotrexate—urinary bladder cancer	0.00037	0.000381	CcSEcCtD
Zolmitriptan—Confusional state—Doxorubicin—urinary bladder cancer	0.000367	0.000377	CcSEcCtD
Zolmitriptan—Decreased appetite—Methotrexate—urinary bladder cancer	0.000365	0.000376	CcSEcCtD
Zolmitriptan—Anaphylactic shock—Doxorubicin—urinary bladder cancer	0.000364	0.000374	CcSEcCtD
Zolmitriptan—Oedema—Doxorubicin—urinary bladder cancer	0.000364	0.000374	CcSEcCtD
Zolmitriptan—Gastrointestinal disorder—Methotrexate—urinary bladder cancer	0.000363	0.000373	CcSEcCtD
Zolmitriptan—Infection—Doxorubicin—urinary bladder cancer	0.000362	0.000372	CcSEcCtD
Zolmitriptan—Pain—Methotrexate—urinary bladder cancer	0.00036	0.00037	CcSEcCtD
Zolmitriptan—Musculoskeletal discomfort—Epirubicin—urinary bladder cancer	0.000358	0.000369	CcSEcCtD
Zolmitriptan—Shock—Doxorubicin—urinary bladder cancer	0.000358	0.000368	CcSEcCtD
Zolmitriptan—Nervous system disorder—Doxorubicin—urinary bladder cancer	0.000357	0.000367	CcSEcCtD
Zolmitriptan—Thrombocytopenia—Doxorubicin—urinary bladder cancer	0.000356	0.000367	CcSEcCtD
Zolmitriptan—Insomnia—Epirubicin—urinary bladder cancer	0.000356	0.000366	CcSEcCtD
Zolmitriptan—Tachycardia—Doxorubicin—urinary bladder cancer	0.000355	0.000365	CcSEcCtD
Zolmitriptan—Skin disorder—Doxorubicin—urinary bladder cancer	0.000354	0.000364	CcSEcCtD
Zolmitriptan—Paraesthesia—Epirubicin—urinary bladder cancer	0.000353	0.000363	CcSEcCtD
Zolmitriptan—Hyperhidrosis—Doxorubicin—urinary bladder cancer	0.000352	0.000362	CcSEcCtD
Zolmitriptan—Dyspnoea—Epirubicin—urinary bladder cancer	0.000351	0.000361	CcSEcCtD
Zolmitriptan—Somnolence—Epirubicin—urinary bladder cancer	0.00035	0.00036	CcSEcCtD
Zolmitriptan—Anorexia—Doxorubicin—urinary bladder cancer	0.000347	0.000357	CcSEcCtD
Zolmitriptan—Feeling abnormal—Methotrexate—urinary bladder cancer	0.000346	0.000356	CcSEcCtD
Zolmitriptan—Dyspepsia—Epirubicin—urinary bladder cancer	0.000346	0.000356	CcSEcCtD
Zolmitriptan—Gastrointestinal pain—Methotrexate—urinary bladder cancer	0.000344	0.000354	CcSEcCtD
Zolmitriptan—Decreased appetite—Epirubicin—urinary bladder cancer	0.000342	0.000352	CcSEcCtD
Zolmitriptan—Gastrointestinal disorder—Epirubicin—urinary bladder cancer	0.00034	0.000349	CcSEcCtD
Zolmitriptan—Constipation—Epirubicin—urinary bladder cancer	0.000336	0.000346	CcSEcCtD
Zolmitriptan—Pain—Epirubicin—urinary bladder cancer	0.000336	0.000346	CcSEcCtD
Zolmitriptan—Urticaria—Methotrexate—urinary bladder cancer	0.000334	0.000343	CcSEcCtD
Zolmitriptan—Abdominal pain—Methotrexate—urinary bladder cancer	0.000332	0.000342	CcSEcCtD
Zolmitriptan—Body temperature increased—Methotrexate—urinary bladder cancer	0.000332	0.000342	CcSEcCtD
Zolmitriptan—Musculoskeletal discomfort—Doxorubicin—urinary bladder cancer	0.000332	0.000341	CcSEcCtD
Zolmitriptan—Insomnia—Doxorubicin—urinary bladder cancer	0.000329	0.000339	CcSEcCtD
Zolmitriptan—Paraesthesia—Doxorubicin—urinary bladder cancer	0.000327	0.000336	CcSEcCtD
Zolmitriptan—Dyspnoea—Doxorubicin—urinary bladder cancer	0.000325	0.000334	CcSEcCtD
Zolmitriptan—Feeling abnormal—Epirubicin—urinary bladder cancer	0.000324	0.000333	CcSEcCtD
Zolmitriptan—Somnolence—Doxorubicin—urinary bladder cancer	0.000324	0.000333	CcSEcCtD
Zolmitriptan—Gastrointestinal pain—Epirubicin—urinary bladder cancer	0.000322	0.000331	CcSEcCtD
Zolmitriptan—Dyspepsia—Doxorubicin—urinary bladder cancer	0.00032	0.00033	CcSEcCtD
Zolmitriptan—Decreased appetite—Doxorubicin—urinary bladder cancer	0.000316	0.000325	CcSEcCtD
Zolmitriptan—Gastrointestinal disorder—Doxorubicin—urinary bladder cancer	0.000314	0.000323	CcSEcCtD
Zolmitriptan—Urticaria—Epirubicin—urinary bladder cancer	0.000313	0.000321	CcSEcCtD
Zolmitriptan—Constipation—Doxorubicin—urinary bladder cancer	0.000311	0.00032	CcSEcCtD
Zolmitriptan—Pain—Doxorubicin—urinary bladder cancer	0.000311	0.00032	CcSEcCtD
Zolmitriptan—Abdominal pain—Epirubicin—urinary bladder cancer	0.000311	0.00032	CcSEcCtD
Zolmitriptan—Body temperature increased—Epirubicin—urinary bladder cancer	0.000311	0.00032	CcSEcCtD
Zolmitriptan—Hypersensitivity—Methotrexate—urinary bladder cancer	0.00031	0.000319	CcSEcCtD
Zolmitriptan—Asthenia—Methotrexate—urinary bladder cancer	0.000302	0.00031	CcSEcCtD
Zolmitriptan—Feeling abnormal—Doxorubicin—urinary bladder cancer	0.0003	0.000308	CcSEcCtD
Zolmitriptan—Gastrointestinal pain—Doxorubicin—urinary bladder cancer	0.000298	0.000306	CcSEcCtD
Zolmitriptan—Pruritus—Methotrexate—urinary bladder cancer	0.000297	0.000306	CcSEcCtD
Zolmitriptan—Hypersensitivity—Epirubicin—urinary bladder cancer	0.00029	0.000298	CcSEcCtD
Zolmitriptan—Urticaria—Doxorubicin—urinary bladder cancer	0.000289	0.000297	CcSEcCtD
Zolmitriptan—Abdominal pain—Doxorubicin—urinary bladder cancer	0.000288	0.000296	CcSEcCtD
Zolmitriptan—Body temperature increased—Doxorubicin—urinary bladder cancer	0.000288	0.000296	CcSEcCtD
Zolmitriptan—Diarrhoea—Methotrexate—urinary bladder cancer	0.000288	0.000296	CcSEcCtD
Zolmitriptan—Asthenia—Epirubicin—urinary bladder cancer	0.000282	0.00029	CcSEcCtD
Zolmitriptan—Pruritus—Epirubicin—urinary bladder cancer	0.000278	0.000286	CcSEcCtD
Zolmitriptan—Dizziness—Methotrexate—urinary bladder cancer	0.000278	0.000286	CcSEcCtD
Zolmitriptan—Diarrhoea—Epirubicin—urinary bladder cancer	0.000269	0.000277	CcSEcCtD
Zolmitriptan—Hypersensitivity—Doxorubicin—urinary bladder cancer	0.000268	0.000276	CcSEcCtD
Zolmitriptan—Vomiting—Methotrexate—urinary bladder cancer	0.000267	0.000275	CcSEcCtD
Zolmitriptan—Rash—Methotrexate—urinary bladder cancer	0.000265	0.000273	CcSEcCtD
Zolmitriptan—Dermatitis—Methotrexate—urinary bladder cancer	0.000265	0.000272	CcSEcCtD
Zolmitriptan—Headache—Methotrexate—urinary bladder cancer	0.000263	0.000271	CcSEcCtD
Zolmitriptan—Asthenia—Doxorubicin—urinary bladder cancer	0.000261	0.000269	CcSEcCtD
Zolmitriptan—Dizziness—Epirubicin—urinary bladder cancer	0.00026	0.000268	CcSEcCtD
Zolmitriptan—Pruritus—Doxorubicin—urinary bladder cancer	0.000258	0.000265	CcSEcCtD
Zolmitriptan—Vomiting—Epirubicin—urinary bladder cancer	0.00025	0.000257	CcSEcCtD
Zolmitriptan—Nausea—Methotrexate—urinary bladder cancer	0.00025	0.000257	CcSEcCtD
Zolmitriptan—Diarrhoea—Doxorubicin—urinary bladder cancer	0.000249	0.000256	CcSEcCtD
Zolmitriptan—Rash—Epirubicin—urinary bladder cancer	0.000248	0.000255	CcSEcCtD
Zolmitriptan—Dermatitis—Epirubicin—urinary bladder cancer	0.000248	0.000255	CcSEcCtD
Zolmitriptan—Headache—Epirubicin—urinary bladder cancer	0.000246	0.000253	CcSEcCtD
Zolmitriptan—Dizziness—Doxorubicin—urinary bladder cancer	0.000241	0.000248	CcSEcCtD
Zolmitriptan—Nausea—Epirubicin—urinary bladder cancer	0.000234	0.00024	CcSEcCtD
Zolmitriptan—Vomiting—Doxorubicin—urinary bladder cancer	0.000231	0.000238	CcSEcCtD
Zolmitriptan—Rash—Doxorubicin—urinary bladder cancer	0.00023	0.000236	CcSEcCtD
Zolmitriptan—Dermatitis—Doxorubicin—urinary bladder cancer	0.000229	0.000236	CcSEcCtD
Zolmitriptan—Headache—Doxorubicin—urinary bladder cancer	0.000228	0.000235	CcSEcCtD
Zolmitriptan—Nausea—Doxorubicin—urinary bladder cancer	0.000216	0.000222	CcSEcCtD
Zolmitriptan—CYP1A2—Metapathway biotransformation—NAT2—urinary bladder cancer	2.6e-06	0.00363	CbGpPWpGaD
Zolmitriptan—CYP1A2—Aryl Hydrocarbon Receptor—RB1—urinary bladder cancer	2.57e-06	0.00358	CbGpPWpGaD
Zolmitriptan—CYP1A2—Phase II conjugation—GSTP1—urinary bladder cancer	2.42e-06	0.00338	CbGpPWpGaD
Zolmitriptan—HTR1F—Signaling Pathways—HDAC4—urinary bladder cancer	2.4e-06	0.00335	CbGpPWpGaD
Zolmitriptan—MAOA—Metabolism—GSTZ1—urinary bladder cancer	2.35e-06	0.00328	CbGpPWpGaD
Zolmitriptan—HTR1A—SIDS Susceptibility Pathways—CREBBP—urinary bladder cancer	2.23e-06	0.00312	CbGpPWpGaD
Zolmitriptan—MAOA—Metabolism—GSTO2—urinary bladder cancer	2.23e-06	0.00311	CbGpPWpGaD
Zolmitriptan—MAOA—Metabolism—NAT1—urinary bladder cancer	2.23e-06	0.00311	CbGpPWpGaD
Zolmitriptan—CYP1A2—Phase II conjugation—GSTM1—urinary bladder cancer	2.23e-06	0.0031	CbGpPWpGaD
Zolmitriptan—HTR1F—Class A/1 (Rhodopsin-like receptors)—CXCL8—urinary bladder cancer	2.13e-06	0.00297	CbGpPWpGaD
Zolmitriptan—CYP1A2—Aryl Hydrocarbon Receptor—PTGS2—urinary bladder cancer	2.11e-06	0.00294	CbGpPWpGaD
Zolmitriptan—CYP1A2—Biological oxidations—HPGDS—urinary bladder cancer	2.11e-06	0.00294	CbGpPWpGaD
Zolmitriptan—MAOA—SIDS Susceptibility Pathways—CXCL8—urinary bladder cancer	2.09e-06	0.00291	CbGpPWpGaD
Zolmitriptan—CYP1A2—Biological oxidations—GSTT1—urinary bladder cancer	2.04e-06	0.00285	CbGpPWpGaD
Zolmitriptan—MAOA—Metabolism—UGT2B7—urinary bladder cancer	2.04e-06	0.00285	CbGpPWpGaD
Zolmitriptan—HTR1F—Signaling Pathways—GLI1—urinary bladder cancer	2.01e-06	0.00281	CbGpPWpGaD
Zolmitriptan—CYP1A2—Arachidonic acid metabolism—PTGS2—urinary bladder cancer	1.97e-06	0.00275	CbGpPWpGaD
Zolmitriptan—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IL2—urinary bladder cancer	1.95e-06	0.00273	CbGpPWpGaD
Zolmitriptan—CYP1A2—Aryl Hydrocarbon Receptor—CDKN1A—urinary bladder cancer	1.84e-06	0.00257	CbGpPWpGaD
Zolmitriptan—MAOA—Metabolism—CYP4B1—urinary bladder cancer	1.84e-06	0.00256	CbGpPWpGaD
Zolmitriptan—MAOA—SIDS Susceptibility Pathways—EP300—urinary bladder cancer	1.79e-06	0.0025	CbGpPWpGaD
Zolmitriptan—HTR1A—SIDS Susceptibility Pathways—CXCL8—urinary bladder cancer	1.77e-06	0.00247	CbGpPWpGaD
Zolmitriptan—CYP1A2—Aryl Hydrocarbon Receptor Pathway—EP300—urinary bladder cancer	1.75e-06	0.00245	CbGpPWpGaD
Zolmitriptan—CYP1A2—Aryl Hydrocarbon Receptor—EP300—urinary bladder cancer	1.75e-06	0.00245	CbGpPWpGaD
Zolmitriptan—MAOA—Metabolism—SLC19A1—urinary bladder cancer	1.74e-06	0.00242	CbGpPWpGaD
Zolmitriptan—HTR1D—G alpha (i) signalling events—CXCL8—urinary bladder cancer	1.71e-06	0.00239	CbGpPWpGaD
Zolmitriptan—CYP1A2—Aryl Hydrocarbon Receptor—SRC—urinary bladder cancer	1.71e-06	0.00238	CbGpPWpGaD
Zolmitriptan—CYP1A2—Aryl Hydrocarbon Receptor Pathway—SRC—urinary bladder cancer	1.71e-06	0.00238	CbGpPWpGaD
Zolmitriptan—MAOA—Metabolism—PRSS3—urinary bladder cancer	1.69e-06	0.00236	CbGpPWpGaD
Zolmitriptan—HTR1B—G alpha (i) signalling events—CXCL8—urinary bladder cancer	1.68e-06	0.00234	CbGpPWpGaD
Zolmitriptan—HTR1F—GPCR ligand binding—CXCL8—urinary bladder cancer	1.62e-06	0.00226	CbGpPWpGaD
Zolmitriptan—HTR1D—Signaling Pathways—HDAC4—urinary bladder cancer	1.54e-06	0.00214	CbGpPWpGaD
Zolmitriptan—CYP1A2—Aryl Hydrocarbon Receptor—MYC—urinary bladder cancer	1.53e-06	0.00213	CbGpPWpGaD
Zolmitriptan—CYP1A2—Metabolism of lipids and lipoproteins—CYP4B1—urinary bladder cancer	1.52e-06	0.00212	CbGpPWpGaD
Zolmitriptan—HTR1A—SIDS Susceptibility Pathways—EP300—urinary bladder cancer	1.52e-06	0.00212	CbGpPWpGaD
Zolmitriptan—HTR1B—Signaling Pathways—HDAC4—urinary bladder cancer	1.51e-06	0.0021	CbGpPWpGaD
Zolmitriptan—CYP1A2—Aryl Hydrocarbon Receptor Pathway—EGFR—urinary bladder cancer	1.49e-06	0.00208	CbGpPWpGaD
Zolmitriptan—CYP1A2—Aryl Hydrocarbon Receptor—EGFR—urinary bladder cancer	1.49e-06	0.00208	CbGpPWpGaD
Zolmitriptan—MAOA—SIDS Susceptibility Pathways—TNF—urinary bladder cancer	1.45e-06	0.00203	CbGpPWpGaD
Zolmitriptan—CYP1A2—Aryl Hydrocarbon Receptor—TNF—urinary bladder cancer	1.42e-06	0.00199	CbGpPWpGaD
Zolmitriptan—CYP1A2—Aryl Hydrocarbon Receptor Pathway—TNF—urinary bladder cancer	1.42e-06	0.00199	CbGpPWpGaD
Zolmitriptan—CYP1A2—Biological oxidations—GSTP1—urinary bladder cancer	1.42e-06	0.00198	CbGpPWpGaD
Zolmitriptan—CYP1A2—Aryl Hydrocarbon Receptor—KRAS—urinary bladder cancer	1.41e-06	0.00197	CbGpPWpGaD
Zolmitriptan—CYP1A2—Metapathway biotransformation—GSTP1—urinary bladder cancer	1.4e-06	0.00195	CbGpPWpGaD
Zolmitriptan—HTR1F—Signaling Pathways—RBX1—urinary bladder cancer	1.38e-06	0.00193	CbGpPWpGaD
Zolmitriptan—HTR1D—Class A/1 (Rhodopsin-like receptors)—CXCL8—urinary bladder cancer	1.36e-06	0.0019	CbGpPWpGaD
Zolmitriptan—MAOA—Metabolism—TYMP—urinary bladder cancer	1.35e-06	0.00189	CbGpPWpGaD
Zolmitriptan—HTR1B—Class A/1 (Rhodopsin-like receptors)—CXCL8—urinary bladder cancer	1.33e-06	0.00186	CbGpPWpGaD
Zolmitriptan—CYP1A2—Biological oxidations—GSTM1—urinary bladder cancer	1.3e-06	0.00182	CbGpPWpGaD
Zolmitriptan—HTR1F—Signaling Pathways—TSC1—urinary bladder cancer	1.3e-06	0.00181	CbGpPWpGaD
Zolmitriptan—HTR1D—Signaling Pathways—GLI1—urinary bladder cancer	1.29e-06	0.0018	CbGpPWpGaD
Zolmitriptan—CYP1A2—Metapathway biotransformation—GSTM1—urinary bladder cancer	1.28e-06	0.00179	CbGpPWpGaD
Zolmitriptan—HTR1A—G alpha (i) signalling events—CXCL8—urinary bladder cancer	1.28e-06	0.00178	CbGpPWpGaD
Zolmitriptan—HTR1B—Signaling Pathways—GLI1—urinary bladder cancer	1.26e-06	0.00176	CbGpPWpGaD
Zolmitriptan—HTR1F—Signaling Pathways—JAG1—urinary bladder cancer	1.24e-06	0.00172	CbGpPWpGaD
Zolmitriptan—HTR1A—SIDS Susceptibility Pathways—TNF—urinary bladder cancer	1.24e-06	0.00172	CbGpPWpGaD
Zolmitriptan—MAOA—Metabolism—NAT2—urinary bladder cancer	1.22e-06	0.00171	CbGpPWpGaD
Zolmitriptan—CYP1A2—Aryl Hydrocarbon Receptor—HRAS—urinary bladder cancer	1.2e-06	0.00167	CbGpPWpGaD
Zolmitriptan—HTR1A—Signaling Pathways—HDAC4—urinary bladder cancer	1.15e-06	0.0016	CbGpPWpGaD
Zolmitriptan—MAOA—Metabolism—RRM2—urinary bladder cancer	1.06e-06	0.00147	CbGpPWpGaD
Zolmitriptan—HTR1F—GPCR downstream signaling—RHOA—urinary bladder cancer	1.04e-06	0.00146	CbGpPWpGaD
Zolmitriptan—HTR1D—GPCR ligand binding—CXCL8—urinary bladder cancer	1.04e-06	0.00145	CbGpPWpGaD
Zolmitriptan—HTR1A—Class A/1 (Rhodopsin-like receptors)—CXCL8—urinary bladder cancer	1.02e-06	0.00142	CbGpPWpGaD
Zolmitriptan—HTR1B—GPCR ligand binding—CXCL8—urinary bladder cancer	1.02e-06	0.00142	CbGpPWpGaD
Zolmitriptan—MAOA—Transmission across Chemical Synapses—HRAS—urinary bladder cancer	1e-06	0.0014	CbGpPWpGaD
Zolmitriptan—HTR1F—Signaling Pathways—S100B—urinary bladder cancer	1e-06	0.0014	CbGpPWpGaD
Zolmitriptan—MAOA—Metabolism—ENO2—urinary bladder cancer	9.77e-07	0.00136	CbGpPWpGaD
Zolmitriptan—MAOA—Metabolism—HPGDS—urinary bladder cancer	9.77e-07	0.00136	CbGpPWpGaD
Zolmitriptan—HTR1A—Signaling Pathways—GLI1—urinary bladder cancer	9.61e-07	0.00134	CbGpPWpGaD
Zolmitriptan—HTR1F—Signaling by GPCR—RHOA—urinary bladder cancer	9.49e-07	0.00132	CbGpPWpGaD
Zolmitriptan—MAOA—Metabolism—GSTT1—urinary bladder cancer	9.48e-07	0.00132	CbGpPWpGaD
Zolmitriptan—HTR1F—GPCR downstream signaling—CXCL8—urinary bladder cancer	9.17e-07	0.00128	CbGpPWpGaD
Zolmitriptan—HTR1F—Signaling Pathways—NCOR1—urinary bladder cancer	9e-07	0.00125	CbGpPWpGaD
Zolmitriptan—HTR1D—Signaling Pathways—RBX1—urinary bladder cancer	8.83e-07	0.00123	CbGpPWpGaD
Zolmitriptan—HTR1F—GPCR downstream signaling—IL2—urinary bladder cancer	8.76e-07	0.00122	CbGpPWpGaD
Zolmitriptan—CYP1A2—Metabolism—GSTZ1—urinary bladder cancer	8.68e-07	0.00121	CbGpPWpGaD
Zolmitriptan—HTR1B—Signaling Pathways—RBX1—urinary bladder cancer	8.64e-07	0.00121	CbGpPWpGaD
Zolmitriptan—HTR1F—Signaling by GPCR—CXCL8—urinary bladder cancer	8.33e-07	0.00116	CbGpPWpGaD
Zolmitriptan—HTR1D—Signaling Pathways—TSC1—urinary bladder cancer	8.3e-07	0.00116	CbGpPWpGaD
Zolmitriptan—CYP1A2—Metabolism—GSTO2—urinary bladder cancer	8.23e-07	0.00115	CbGpPWpGaD
Zolmitriptan—CYP1A2—Metabolism—NAT1—urinary bladder cancer	8.23e-07	0.00115	CbGpPWpGaD
Zolmitriptan—HTR1B—Signaling Pathways—TSC1—urinary bladder cancer	8.13e-07	0.00113	CbGpPWpGaD
Zolmitriptan—CYP1A2—Metabolism of lipids and lipoproteins—HPGDS—urinary bladder cancer	8.09e-07	0.00113	CbGpPWpGaD
Zolmitriptan—HTR1F—Signaling by GPCR—IL2—urinary bladder cancer	7.96e-07	0.00111	CbGpPWpGaD
Zolmitriptan—HTR1F—Signaling Pathways—TERT—urinary bladder cancer	7.93e-07	0.00111	CbGpPWpGaD
Zolmitriptan—HTR1D—Signaling Pathways—JAG1—urinary bladder cancer	7.9e-07	0.0011	CbGpPWpGaD
Zolmitriptan—MAOA—Metabolism—NQO1—urinary bladder cancer	7.88e-07	0.0011	CbGpPWpGaD
Zolmitriptan—HTR1A—GPCR ligand binding—CXCL8—urinary bladder cancer	7.74e-07	0.00108	CbGpPWpGaD
Zolmitriptan—HTR1B—Signaling Pathways—JAG1—urinary bladder cancer	7.74e-07	0.00108	CbGpPWpGaD
Zolmitriptan—MAOA—Neuronal System—HRAS—urinary bladder cancer	7.69e-07	0.00107	CbGpPWpGaD
Zolmitriptan—CYP1A2—Metabolism—UGT2B7—urinary bladder cancer	7.53e-07	0.00105	CbGpPWpGaD
Zolmitriptan—HTR1F—Signaling Pathways—FGFR3—urinary bladder cancer	7.28e-07	0.00101	CbGpPWpGaD
Zolmitriptan—HTR1F—Signaling Pathways—ESR1—urinary bladder cancer	7.07e-07	0.000986	CbGpPWpGaD
Zolmitriptan—CYP1A2—Metabolism—CYP4B1—urinary bladder cancer	6.78e-07	0.000945	CbGpPWpGaD
Zolmitriptan—HTR1D—GPCR downstream signaling—RHOA—urinary bladder cancer	6.68e-07	0.000932	CbGpPWpGaD
Zolmitriptan—HTR1A—Signaling Pathways—RBX1—urinary bladder cancer	6.59e-07	0.000919	CbGpPWpGaD
Zolmitriptan—MAOA—Metabolism—GSTP1—urinary bladder cancer	6.57e-07	0.000916	CbGpPWpGaD
Zolmitriptan—HTR1B—GPCR downstream signaling—RHOA—urinary bladder cancer	6.54e-07	0.000912	CbGpPWpGaD
Zolmitriptan—CYP1A2—Metabolism—SLC19A1—urinary bladder cancer	6.4e-07	0.000893	CbGpPWpGaD
Zolmitriptan—HTR1D—Signaling Pathways—S100B—urinary bladder cancer	6.4e-07	0.000892	CbGpPWpGaD
Zolmitriptan—HTR1B—Signaling Pathways—S100B—urinary bladder cancer	6.27e-07	0.000874	CbGpPWpGaD
Zolmitriptan—CYP1A2—Metabolism—PRSS3—urinary bladder cancer	6.24e-07	0.00087	CbGpPWpGaD
Zolmitriptan—HTR1F—Signaling Pathways—CREBBP—urinary bladder cancer	6.19e-07	0.000864	CbGpPWpGaD
Zolmitriptan—HTR1A—Signaling Pathways—TSC1—urinary bladder cancer	6.19e-07	0.000864	CbGpPWpGaD
Zolmitriptan—HTR1F—Signaling Pathways—IGF1—urinary bladder cancer	6.12e-07	0.000853	CbGpPWpGaD
Zolmitriptan—MAOA—Metabolism—TYMS—urinary bladder cancer	6.11e-07	0.000852	CbGpPWpGaD
Zolmitriptan—HTR1F—Signaling by GPCR—EGFR—urinary bladder cancer	6.09e-07	0.000849	CbGpPWpGaD
Zolmitriptan—HTR1D—Signaling by GPCR—RHOA—urinary bladder cancer	6.07e-07	0.000846	CbGpPWpGaD
Zolmitriptan—MAOA—Metabolism—NCOR1—urinary bladder cancer	6.04e-07	0.000842	CbGpPWpGaD
Zolmitriptan—MAOA—Metabolism—GSTM1—urinary bladder cancer	6.04e-07	0.000842	CbGpPWpGaD
Zolmitriptan—HTR1B—Signaling by GPCR—RHOA—urinary bladder cancer	5.94e-07	0.000828	CbGpPWpGaD
Zolmitriptan—HTR1A—Signaling Pathways—JAG1—urinary bladder cancer	5.89e-07	0.000822	CbGpPWpGaD
Zolmitriptan—HTR1D—GPCR downstream signaling—CXCL8—urinary bladder cancer	5.86e-07	0.000818	CbGpPWpGaD
Zolmitriptan—MAOA—Metabolism—GPX1—urinary bladder cancer	5.78e-07	0.000806	CbGpPWpGaD
Zolmitriptan—HTR1D—Signaling Pathways—NCOR1—urinary bladder cancer	5.75e-07	0.000803	CbGpPWpGaD
Zolmitriptan—HTR1F—Signaling by GPCR—KRAS—urinary bladder cancer	5.75e-07	0.000802	CbGpPWpGaD
Zolmitriptan—HTR1B—GPCR downstream signaling—CXCL8—urinary bladder cancer	5.74e-07	0.000801	CbGpPWpGaD
Zolmitriptan—MAOA—Metabolism—ERCC2—urinary bladder cancer	5.68e-07	0.000792	CbGpPWpGaD
Zolmitriptan—HTR1B—Signaling Pathways—NCOR1—urinary bladder cancer	5.63e-07	0.000786	CbGpPWpGaD
Zolmitriptan—HTR1D—GPCR downstream signaling—IL2—urinary bladder cancer	5.6e-07	0.000782	CbGpPWpGaD
Zolmitriptan—HTR1F—Signaling Pathways—RHOA—urinary bladder cancer	5.6e-07	0.000782	CbGpPWpGaD
Zolmitriptan—HTR1B—GPCR downstream signaling—IL2—urinary bladder cancer	5.49e-07	0.000765	CbGpPWpGaD
Zolmitriptan—MAOA—Metabolism—MTHFR—urinary bladder cancer	5.34e-07	0.000744	CbGpPWpGaD
Zolmitriptan—HTR1D—Signaling by GPCR—CXCL8—urinary bladder cancer	5.33e-07	0.000743	CbGpPWpGaD
Zolmitriptan—HTR1B—Signaling by GPCR—CXCL8—urinary bladder cancer	5.21e-07	0.000727	CbGpPWpGaD
Zolmitriptan—HTR1F—Signaling Pathways—ERBB2—urinary bladder cancer	5.19e-07	0.000724	CbGpPWpGaD
Zolmitriptan—HTR1D—Signaling by GPCR—IL2—urinary bladder cancer	5.09e-07	0.00071	CbGpPWpGaD
Zolmitriptan—HTR1D—Signaling Pathways—TERT—urinary bladder cancer	5.07e-07	0.000707	CbGpPWpGaD
Zolmitriptan—CYP1A2—Metabolism of lipids and lipoproteins—NCOR1—urinary bladder cancer	5e-07	0.000697	CbGpPWpGaD
Zolmitriptan—CYP1A2—Metabolism—TYMP—urinary bladder cancer	4.99e-07	0.000695	CbGpPWpGaD
Zolmitriptan—HTR1B—Signaling by GPCR—IL2—urinary bladder cancer	4.98e-07	0.000695	CbGpPWpGaD
Zolmitriptan—HTR1A—GPCR downstream signaling—RHOA—urinary bladder cancer	4.98e-07	0.000695	CbGpPWpGaD
Zolmitriptan—HTR1B—Signaling Pathways—TERT—urinary bladder cancer	4.97e-07	0.000693	CbGpPWpGaD
Zolmitriptan—HTR1F—Signaling Pathways—CXCL8—urinary bladder cancer	4.92e-07	0.000686	CbGpPWpGaD
Zolmitriptan—HTR1F—Signaling by GPCR—HRAS—urinary bladder cancer	4.89e-07	0.000682	CbGpPWpGaD
Zolmitriptan—CYP1A2—Metabolism of lipids and lipoproteins—GPX1—urinary bladder cancer	4.79e-07	0.000668	CbGpPWpGaD
Zolmitriptan—HTR1A—Signaling Pathways—S100B—urinary bladder cancer	4.77e-07	0.000666	CbGpPWpGaD
Zolmitriptan—HTR1F—Signaling Pathways—IL2—urinary bladder cancer	4.7e-07	0.000656	CbGpPWpGaD
Zolmitriptan—HTR1D—Signaling Pathways—FGFR3—urinary bladder cancer	4.65e-07	0.000649	CbGpPWpGaD
Zolmitriptan—HTR1F—Signaling Pathways—CCND1—urinary bladder cancer	4.58e-07	0.000639	CbGpPWpGaD
Zolmitriptan—HTR1B—Signaling Pathways—FGFR3—urinary bladder cancer	4.56e-07	0.000636	CbGpPWpGaD
Zolmitriptan—HTR1A—Signaling by GPCR—RHOA—urinary bladder cancer	4.52e-07	0.000631	CbGpPWpGaD
Zolmitriptan—HTR1D—Signaling Pathways—ESR1—urinary bladder cancer	4.52e-07	0.00063	CbGpPWpGaD
Zolmitriptan—CYP1A2—Metabolism—NAT2—urinary bladder cancer	4.51e-07	0.000629	CbGpPWpGaD
Zolmitriptan—HTR1F—Signaling Pathways—MMP9—urinary bladder cancer	4.45e-07	0.000621	CbGpPWpGaD
Zolmitriptan—HTR1F—Signaling Pathways—CDKN1A—urinary bladder cancer	4.43e-07	0.000618	CbGpPWpGaD
Zolmitriptan—HTR1B—Signaling Pathways—ESR1—urinary bladder cancer	4.43e-07	0.000617	CbGpPWpGaD
Zolmitriptan—HTR1F—Signaling Pathways—PTEN—urinary bladder cancer	4.42e-07	0.000617	CbGpPWpGaD
Zolmitriptan—HTR1A—GPCR downstream signaling—CXCL8—urinary bladder cancer	4.37e-07	0.00061	CbGpPWpGaD
Zolmitriptan—MAOA—Metabolism—PPARG—urinary bladder cancer	4.33e-07	0.000604	CbGpPWpGaD
Zolmitriptan—HTR1A—Signaling Pathways—NCOR1—urinary bladder cancer	4.29e-07	0.000599	CbGpPWpGaD
Zolmitriptan—HTR1F—Signaling Pathways—EP300—urinary bladder cancer	4.22e-07	0.000588	CbGpPWpGaD
Zolmitriptan—HTR1A—GPCR downstream signaling—IL2—urinary bladder cancer	4.18e-07	0.000583	CbGpPWpGaD
Zolmitriptan—MAOA—Metabolism—CREBBP—urinary bladder cancer	4.16e-07	0.00058	CbGpPWpGaD
Zolmitriptan—HTR1F—Signaling Pathways—SRC—urinary bladder cancer	4.1e-07	0.000572	CbGpPWpGaD
Zolmitriptan—HTR1A—Signaling by GPCR—CXCL8—urinary bladder cancer	3.97e-07	0.000554	CbGpPWpGaD
Zolmitriptan—HTR1D—Signaling Pathways—CREBBP—urinary bladder cancer	3.96e-07	0.000552	CbGpPWpGaD
Zolmitriptan—HTR1D—Signaling Pathways—IGF1—urinary bladder cancer	3.91e-07	0.000546	CbGpPWpGaD
Zolmitriptan—HTR1D—Signaling by GPCR—EGFR—urinary bladder cancer	3.89e-07	0.000543	CbGpPWpGaD
Zolmitriptan—CYP1A2—Metabolism—RRM2—urinary bladder cancer	3.89e-07	0.000543	CbGpPWpGaD
Zolmitriptan—HTR1B—Signaling Pathways—CREBBP—urinary bladder cancer	3.88e-07	0.000541	CbGpPWpGaD
Zolmitriptan—HTR1B—Signaling Pathways—IGF1—urinary bladder cancer	3.83e-07	0.000534	CbGpPWpGaD
Zolmitriptan—HTR1B—Signaling by GPCR—EGFR—urinary bladder cancer	3.81e-07	0.000532	CbGpPWpGaD
Zolmitriptan—HTR1A—Signaling by GPCR—IL2—urinary bladder cancer	3.8e-07	0.000529	CbGpPWpGaD
Zolmitriptan—HTR1A—Signaling Pathways—TERT—urinary bladder cancer	3.78e-07	0.000528	CbGpPWpGaD
Zolmitriptan—HTR1D—Signaling by GPCR—KRAS—urinary bladder cancer	3.68e-07	0.000513	CbGpPWpGaD
Zolmitriptan—HTR1F—Signaling Pathways—MYC—urinary bladder cancer	3.68e-07	0.000513	CbGpPWpGaD
Zolmitriptan—CYP1A2—Metabolism—ENO2—urinary bladder cancer	3.6e-07	0.000503	CbGpPWpGaD
Zolmitriptan—CYP1A2—Metabolism—HPGDS—urinary bladder cancer	3.6e-07	0.000503	CbGpPWpGaD
Zolmitriptan—HTR1B—Signaling by GPCR—KRAS—urinary bladder cancer	3.6e-07	0.000502	CbGpPWpGaD
Zolmitriptan—HTR1F—Signaling Pathways—EGFR—urinary bladder cancer	3.6e-07	0.000502	CbGpPWpGaD
Zolmitriptan—CYP1A2—Metabolism of lipids and lipoproteins—PPARG—urinary bladder cancer	3.58e-07	0.0005	CbGpPWpGaD
Zolmitriptan—HTR1D—Signaling Pathways—RHOA—urinary bladder cancer	3.58e-07	0.0005	CbGpPWpGaD
Zolmitriptan—HTR1B—Signaling Pathways—RHOA—urinary bladder cancer	3.51e-07	0.000489	CbGpPWpGaD
Zolmitriptan—CYP1A2—Metabolism—GSTT1—urinary bladder cancer	3.5e-07	0.000488	CbGpPWpGaD
Zolmitriptan—HTR1A—Signaling Pathways—FGFR3—urinary bladder cancer	3.47e-07	0.000484	CbGpPWpGaD
Zolmitriptan—CYP1A2—Metabolism of lipids and lipoproteins—CREBBP—urinary bladder cancer	3.44e-07	0.00048	CbGpPWpGaD
Zolmitriptan—MAOA—Metabolism—PTGS2—urinary bladder cancer	3.4e-07	0.000475	CbGpPWpGaD
Zolmitriptan—HTR1F—Signaling Pathways—KRAS—urinary bladder cancer	3.4e-07	0.000474	CbGpPWpGaD
Zolmitriptan—HTR1A—Signaling Pathways—ESR1—urinary bladder cancer	3.37e-07	0.00047	CbGpPWpGaD
Zolmitriptan—HTR1D—Signaling Pathways—ERBB2—urinary bladder cancer	3.32e-07	0.000463	CbGpPWpGaD
Zolmitriptan—HTR1B—Signaling Pathways—ERBB2—urinary bladder cancer	3.25e-07	0.000453	CbGpPWpGaD
Zolmitriptan—HTR1D—Signaling Pathways—CXCL8—urinary bladder cancer	3.15e-07	0.000439	CbGpPWpGaD
Zolmitriptan—HTR1D—Signaling by GPCR—HRAS—urinary bladder cancer	3.13e-07	0.000436	CbGpPWpGaD
Zolmitriptan—HTR1B—Signaling Pathways—CXCL8—urinary bladder cancer	3.08e-07	0.00043	CbGpPWpGaD
Zolmitriptan—HTR1B—Signaling by GPCR—HRAS—urinary bladder cancer	3.06e-07	0.000427	CbGpPWpGaD
Zolmitriptan—HTR1F—Signaling Pathways—TP53—urinary bladder cancer	3.02e-07	0.000421	CbGpPWpGaD
Zolmitriptan—HTR1D—Signaling Pathways—IL2—urinary bladder cancer	3.01e-07	0.000419	CbGpPWpGaD
Zolmitriptan—MAOA—Metabolism—PTEN—urinary bladder cancer	2.97e-07	0.000414	CbGpPWpGaD
Zolmitriptan—HTR1A—Signaling Pathways—CREBBP—urinary bladder cancer	2.95e-07	0.000412	CbGpPWpGaD
Zolmitriptan—HTR1B—Signaling Pathways—IL2—urinary bladder cancer	2.94e-07	0.000411	CbGpPWpGaD
Zolmitriptan—HTR1D—Signaling Pathways—CCND1—urinary bladder cancer	2.93e-07	0.000409	CbGpPWpGaD
Zolmitriptan—HTR1A—Signaling Pathways—IGF1—urinary bladder cancer	2.92e-07	0.000407	CbGpPWpGaD
Zolmitriptan—CYP1A2—Metabolism—NQO1—urinary bladder cancer	2.91e-07	0.000405	CbGpPWpGaD
Zolmitriptan—HTR1A—Signaling by GPCR—EGFR—urinary bladder cancer	2.9e-07	0.000405	CbGpPWpGaD
Zolmitriptan—HTR1F—Signaling Pathways—HRAS—urinary bladder cancer	2.89e-07	0.000403	CbGpPWpGaD
Zolmitriptan—HTR1B—Signaling Pathways—CCND1—urinary bladder cancer	2.87e-07	0.0004	CbGpPWpGaD
Zolmitriptan—HTR1D—Signaling Pathways—MMP9—urinary bladder cancer	2.85e-07	0.000397	CbGpPWpGaD
Zolmitriptan—HTR1D—Signaling Pathways—CDKN1A—urinary bladder cancer	2.84e-07	0.000395	CbGpPWpGaD
Zolmitriptan—MAOA—Metabolism—EP300—urinary bladder cancer	2.83e-07	0.000395	CbGpPWpGaD
Zolmitriptan—HTR1D—Signaling Pathways—PTEN—urinary bladder cancer	2.83e-07	0.000395	CbGpPWpGaD
Zolmitriptan—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—urinary bladder cancer	2.82e-07	0.000393	CbGpPWpGaD
Zolmitriptan—HTR1B—Signaling Pathways—MMP9—urinary bladder cancer	2.79e-07	0.000389	CbGpPWpGaD
Zolmitriptan—HTR1B—Signaling Pathways—CDKN1A—urinary bladder cancer	2.78e-07	0.000387	CbGpPWpGaD
Zolmitriptan—HTR1B—Signaling Pathways—PTEN—urinary bladder cancer	2.77e-07	0.000386	CbGpPWpGaD
Zolmitriptan—HTR1A—Signaling by GPCR—KRAS—urinary bladder cancer	2.74e-07	0.000383	CbGpPWpGaD
Zolmitriptan—HTR1D—Signaling Pathways—EP300—urinary bladder cancer	2.7e-07	0.000376	CbGpPWpGaD
Zolmitriptan—HTR1A—Signaling Pathways—RHOA—urinary bladder cancer	2.67e-07	0.000373	CbGpPWpGaD
Zolmitriptan—HTR1B—Signaling Pathways—EP300—urinary bladder cancer	2.64e-07	0.000368	CbGpPWpGaD
Zolmitriptan—HTR1D—Signaling Pathways—SRC—urinary bladder cancer	2.62e-07	0.000366	CbGpPWpGaD
Zolmitriptan—HTR1B—Signaling Pathways—SRC—urinary bladder cancer	2.57e-07	0.000358	CbGpPWpGaD
Zolmitriptan—HTR1A—Signaling Pathways—ERBB2—urinary bladder cancer	2.47e-07	0.000345	CbGpPWpGaD
Zolmitriptan—CYP1A2—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	2.46e-07	0.000343	CbGpPWpGaD
Zolmitriptan—CYP1A2—Metabolism—GSTP1—urinary bladder cancer	2.42e-07	0.000338	CbGpPWpGaD
Zolmitriptan—HTR1D—Signaling Pathways—MYC—urinary bladder cancer	2.35e-07	0.000328	CbGpPWpGaD
Zolmitriptan—HTR1A—Signaling Pathways—CXCL8—urinary bladder cancer	2.35e-07	0.000327	CbGpPWpGaD
Zolmitriptan—CYP1A2—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	2.34e-07	0.000327	CbGpPWpGaD
Zolmitriptan—HTR1A—Signaling by GPCR—HRAS—urinary bladder cancer	2.33e-07	0.000325	CbGpPWpGaD
Zolmitriptan—HTR1B—Signaling Pathways—MYC—urinary bladder cancer	2.3e-07	0.000321	CbGpPWpGaD
Zolmitriptan—HTR1D—Signaling Pathways—EGFR—urinary bladder cancer	2.3e-07	0.000321	CbGpPWpGaD
Zolmitriptan—CYP1A2—Metabolism—TYMS—urinary bladder cancer	2.25e-07	0.000314	CbGpPWpGaD
Zolmitriptan—HTR1B—Signaling Pathways—EGFR—urinary bladder cancer	2.25e-07	0.000314	CbGpPWpGaD
Zolmitriptan—HTR1A—Signaling Pathways—IL2—urinary bladder cancer	2.24e-07	0.000313	CbGpPWpGaD
Zolmitriptan—CYP1A2—Metabolism—NCOR1—urinary bladder cancer	2.23e-07	0.000311	CbGpPWpGaD
Zolmitriptan—CYP1A2—Metabolism—GSTM1—urinary bladder cancer	2.23e-07	0.000311	CbGpPWpGaD
Zolmitriptan—HTR1A—Signaling Pathways—CCND1—urinary bladder cancer	2.19e-07	0.000305	CbGpPWpGaD
Zolmitriptan—HTR1D—Signaling Pathways—KRAS—urinary bladder cancer	2.17e-07	0.000303	CbGpPWpGaD
Zolmitriptan—CYP1A2—Metabolism—GPX1—urinary bladder cancer	2.13e-07	0.000297	CbGpPWpGaD
Zolmitriptan—HTR1B—Signaling Pathways—KRAS—urinary bladder cancer	2.13e-07	0.000297	CbGpPWpGaD
Zolmitriptan—HTR1A—Signaling Pathways—MMP9—urinary bladder cancer	2.12e-07	0.000296	CbGpPWpGaD
Zolmitriptan—HTR1A—Signaling Pathways—CDKN1A—urinary bladder cancer	2.11e-07	0.000295	CbGpPWpGaD
Zolmitriptan—HTR1A—Signaling Pathways—PTEN—urinary bladder cancer	2.11e-07	0.000294	CbGpPWpGaD
Zolmitriptan—CYP1A2—Metabolism—ERCC2—urinary bladder cancer	2.09e-07	0.000292	CbGpPWpGaD
Zolmitriptan—HTR1A—Signaling Pathways—EP300—urinary bladder cancer	2.01e-07	0.000281	CbGpPWpGaD
Zolmitriptan—CYP1A2—Metabolism—MTHFR—urinary bladder cancer	1.97e-07	0.000274	CbGpPWpGaD
Zolmitriptan—HTR1A—Signaling Pathways—SRC—urinary bladder cancer	1.96e-07	0.000273	CbGpPWpGaD
Zolmitriptan—HTR1D—Signaling Pathways—TP53—urinary bladder cancer	1.93e-07	0.000269	CbGpPWpGaD
Zolmitriptan—HTR1B—Signaling Pathways—TP53—urinary bladder cancer	1.89e-07	0.000264	CbGpPWpGaD
Zolmitriptan—HTR1D—Signaling Pathways—HRAS—urinary bladder cancer	1.85e-07	0.000258	CbGpPWpGaD
Zolmitriptan—HTR1B—Signaling Pathways—HRAS—urinary bladder cancer	1.81e-07	0.000252	CbGpPWpGaD
Zolmitriptan—HTR1A—Signaling Pathways—MYC—urinary bladder cancer	1.75e-07	0.000245	CbGpPWpGaD
Zolmitriptan—HTR1A—Signaling Pathways—EGFR—urinary bladder cancer	1.72e-07	0.000239	CbGpPWpGaD
Zolmitriptan—HTR1A—Signaling Pathways—KRAS—urinary bladder cancer	1.62e-07	0.000226	CbGpPWpGaD
Zolmitriptan—CYP1A2—Metabolism—PPARG—urinary bladder cancer	1.6e-07	0.000223	CbGpPWpGaD
Zolmitriptan—CYP1A2—Metabolism—CREBBP—urinary bladder cancer	1.53e-07	0.000214	CbGpPWpGaD
Zolmitriptan—HTR1A—Signaling Pathways—TP53—urinary bladder cancer	1.44e-07	0.000201	CbGpPWpGaD
Zolmitriptan—HTR1A—Signaling Pathways—HRAS—urinary bladder cancer	1.38e-07	0.000192	CbGpPWpGaD
Zolmitriptan—CYP1A2—Metabolism—PTGS2—urinary bladder cancer	1.26e-07	0.000175	CbGpPWpGaD
Zolmitriptan—CYP1A2—Metabolism—PTEN—urinary bladder cancer	1.09e-07	0.000153	CbGpPWpGaD
Zolmitriptan—CYP1A2—Metabolism—EP300—urinary bladder cancer	1.04e-07	0.000146	CbGpPWpGaD
